Home › Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations
 

Keywords :   


Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations

2015-10-20 16:35:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. New Data Will Also be Presented from Phase 2a C-CREST Trials of Mercks Investigational Triple-Combination Chronic Hepatitis C Therapies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical trials of its investigational treatment portfolio for chronic hepatitis C virus (HCV) are scheduled to be presented at The Liver Meeting 2015 (the 66th annual scientific congress of the American Association for the Study of Liver Diseases) in San Francisco, from Nov. 13-17, 2015. Mercks late-stage investigational portfolio includes elbasvir/grazoprevir1, MK-36822 and MK-84083. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results including data present

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.11Tropical Storm Sara Graphics
15.11Tropical Storm Sara Forecast Discussion Number 8
15.11Tropical Storm Sara Wind Speed Probabilities Number 8
15.11Tropical Storm Sara Public Advisory Number 8
15.11 20213 105S P7905-P
15.11 ()
15.11Mizuno Energy 25.5
15.11
More »